409 related articles for article (PubMed ID: 31894140)
1. Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery.
Powley IR; Patel M; Miles G; Pringle H; Howells L; Thomas A; Kettleborough C; Bryans J; Hammonds T; MacFarlane M; Pritchard C
Br J Cancer; 2020 Mar; 122(6):735-744. PubMed ID: 31894140
[TBL] [Abstract][Full Text] [Related]
2. Evaluating and comparing immunostaining and computational methods for spatial profiling of drug response in patient-derived explants.
Miles GJ; Powley I; Mohammed S; Howells L; Pringle JH; Hammonds T; MacFarlane M; Pritchard C
Lab Invest; 2021 Mar; 101(3):396-407. PubMed ID: 33318618
[TBL] [Abstract][Full Text] [Related]
3. Development of a patient-derived explant model for prediction of drug responses in endometrial cancer.
Collins A; Miles GJ; Powley IR; Hew R; Pringle JH; MacFarlane M; Pritchard C; Moss EL
Gynecol Oncol; 2021 Feb; 160(2):557-567. PubMed ID: 33309417
[TBL] [Abstract][Full Text] [Related]
4. Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients.
Viticchié G; Powley I; Demetriou C; Cooper J; Butterworth M; Patel M; Abid N; Miles G; Howells L; Pringle H; MacFarlane M; Pritchard C
J Vis Exp; 2021 Feb; (168):. PubMed ID: 33616105
[TBL] [Abstract][Full Text] [Related]
5. Patient-derived tumour xenografts for breast cancer drug discovery.
Cassidy JW; Batra AS; Greenwood W; Bruna A
Endocr Relat Cancer; 2016 Dec; 23(12):T259-T270. PubMed ID: 27702751
[TBL] [Abstract][Full Text] [Related]
6. An optimised patient-derived explant platform for breast cancer reflects clinical responses to chemotherapy and antibody-directed therapy.
Demetriou C; Abid N; Butterworth M; Lezina L; Sandhu P; Howells L; Powley IR; Pringle JH; Sidat Z; Qassid O; Purnell D; Kaushik M; Duckworth K; Hartshorn H; Thomas A; Shaw JA; MacFarlane M; Pritchard C; Miles GJ
Sci Rep; 2024 Jun; 14(1):12833. PubMed ID: 38834809
[TBL] [Abstract][Full Text] [Related]
7. Personalization of the medical treatment of solid tumours using patient-derived tumour explants (Review).
Louandre C; Donnadieu J; Lachaier E; Page C; Chauffert B; Galmiche A
Int J Oncol; 2016 Mar; 48(3):895-9. PubMed ID: 26783093
[TBL] [Abstract][Full Text] [Related]
8. Accelerating precision anti-cancer therapy by time-lapse and label-free 3D tumor slice culture platform.
Xing F; Liu YC; Huang S; Lyu X; Su SM; Chan UI; Wu PC; Yan Y; Ai N; Li J; Zhao M; Rajendran BK; Liu J; Shao F; Sun H; Choi TK; Zhu W; Luo G; Liu S; Xu L; Chan KL; Zhao Q; Miao K; Luo KQ; Ge W; Xu X; Wang G; Liu TM; Deng CX
Theranostics; 2021; 11(19):9415-9430. PubMed ID: 34646378
[TBL] [Abstract][Full Text] [Related]
9. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
10. Zebrafish Xenografts for Drug Discovery and Personalized Medicine.
Xiao J; Glasgow E; Agarwal S
Trends Cancer; 2020 Jul; 6(7):569-579. PubMed ID: 32312681
[TBL] [Abstract][Full Text] [Related]
11. Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of Invasion.
Darrigues E; Zhao EH; De Loose A; Lee MP; Borrelli MJ; Eoff RL; Galileo DS; Penthala NR; Crooks PA; Rodriguez A
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639060
[TBL] [Abstract][Full Text] [Related]
12. Patient-Derived Organoids as a Model for Cancer Drug Discovery.
Rae C; Amato F; Braconi C
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33801782
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiologically relevant in vitro tumor models for drug screening.
Das V; Bruzzese F; Konečný P; Iannelli F; Budillon A; Hajdúch M
Drug Discov Today; 2015 Jul; 20(7):848-55. PubMed ID: 25908576
[TBL] [Abstract][Full Text] [Related]
14. Application of Cancer Organoid Model for Drug Screening and Personalized Therapy.
Kondo J; Inoue M
Cells; 2019 May; 8(5):. PubMed ID: 31108870
[TBL] [Abstract][Full Text] [Related]
15. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
16. Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation.
Alymani NA; Smith MD; Williams DJ; Petty RD
Eur J Cancer; 2010 Mar; 46(5):869-79. PubMed ID: 20138504
[TBL] [Abstract][Full Text] [Related]
17. A patient-derived explant (PDE) model of hormone-dependent cancer.
Centenera MM; Hickey TE; Jindal S; Ryan NK; Ravindranathan P; Mohammed H; Robinson JL; Schiewer MJ; Ma S; Kapur P; Sutherland PD; Hoffmann CE; Roehrborn CG; Gomella LG; Carroll JS; Birrell SN; Knudsen KE; Raj GV; Butler LM; Tilley WD
Mol Oncol; 2018 Sep; 12(9):1608-1622. PubMed ID: 30117261
[TBL] [Abstract][Full Text] [Related]
18. [Spheroids to organoids: Solid cancer models for anticancer drug discovery].
Alzeeb G; Corcos L; Le Jossic-Corcos C
Bull Cancer; 2022 Jan; 109(1):49-57. PubMed ID: 34848046
[TBL] [Abstract][Full Text] [Related]
19. Patient-Derived Organoids for Precision Cancer Immunotherapy.
Grönholm M; Feodoroff M; Antignani G; Martins B; Hamdan F; Cerullo V
Cancer Res; 2021 Jun; 81(12):3149-3155. PubMed ID: 33687948
[TBL] [Abstract][Full Text] [Related]
20. Developments in preclinical cancer imaging: innovating the discovery of therapeutics.
Conway JR; Carragher NO; Timpson P
Nat Rev Cancer; 2014 May; 14(5):314-28. PubMed ID: 24739578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
